Form 4: Merck & Co. Completes Acquisition of Harpoon Therapeutics in Merger

Merck & Co., Inc. finalizes the acquisition of Harpoon Therapeutics through a merger, resulting in Merck becoming the direct beneficial owner of 100% of Harpoon's common stock.

Summary

• On March 11, 2024, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., completed the acquisition of Harpoon Therapeutics, Inc. through a merger.
• Hawaii Merger Sub, Inc., another subsidiary of Merck Sharp & Dohme LLC, merged with Harpoon Therapeutics.
• Upon completion of the merger, each outstanding share of Harpoon's common stock was cancelled.
• Merck Sharp & Dohme LLC became the direct beneficial owner of 1,000 shares of common stock of the surviving corporation, representing 100% ownership.
• Merck & Co., Inc. is the indirect beneficial owner of these shares.

Sentiment

Score: 7

Explanation: The document reflects a positive outcome for Merck as it successfully acquired Harpoon Therapeutics. The sentiment is neutral to positive as it represents a strategic move for the company.

Positives

• Merck successfully acquired Harpoon Therapeutics, expanding its portfolio.

Future Outlook

The document does not contain any specific forward-looking statements beyond the completion of the merger.

Industry Context

This acquisition reflects a trend in the pharmaceutical industry where larger companies acquire smaller biotech firms to gain access to promising drug candidates and technologies.

Comparison to Industry Standards

• Acquisitions of biotech companies by larger pharmaceutical firms are common in the industry.
• Comparable acquisitions include Pfizer's acquisition of Seagen and Amgen's acquisition of Horizon Therapeutics, both aimed at expanding their respective pipelines and market presence.

Stakeholder Impact

• Shareholders of Harpoon Therapeutics received consideration as part of the merger agreement.
• Employees of Harpoon Therapeutics may experience changes as a result of the acquisition by Merck.

Key Dates